Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals Inc., develops and markets Nexavar tablet, a multiple kinase inhibitor for the treatment of liver cancer and advanced kidney cancer; and Stivarga tablets to treat metastatic colorectal cancer. It is also conducting Phase III clinical trial on Nexavar for the treatment of liver, kidney, thyroid, breast, and non-small cell lung cancers;
since Doxorubicin is so, modern day cancer probably consumes the stuff for energy. Anyway Celsion can offer these guys something with a recipe for encapsulating nexavar and applying RFA. Doxorubicin is like using Phermeldihyde to pickle livers....
Bayer buying ONYX likely going to tower over ILCA 9/14. Don't think Dr.Poon going to bring anything new to the table. Hopefully Celsion goes big on its " gathering after the gathering".
Wonder why HISUN is not going to be in attendance ?